this company every year lose big money - no profit no dividend big debt- syndicate goreng wan, one of my friend 70 yr old says u buy u die.. trap newbies one
Covid-19 vaccine dampens sentiment on glove counters in morning trade KUALA LUMPUR (Nov 16): Glove stocks were headed lower in Bursa Malaysia's morning trading session today due to the news flow of Covid-19 vaccine progress, which dampened sentiment on the counters. As at the time of writing, glove stocks were among the top losers today. At 11.53am, Hartalega Holdings Bhd, being the second top loser, was down 4.29% or 66 sen at RM14.72, bringing its market capitalisation lower to RM50.54 billion. It saw some 2.78 million shares traded. In the fourth place was Supermax Corp Bhd, which fell 5.24% or 46 sen to RM8.32, with a market value of RM22.72 billion. More than seven months after the World Health Organization (WHO) declared the Covid-19 outbreak in China a “public health emergency of international concern”, the global economy continues to reel from the impact of the virus. Meanwhile, Top Glove Corp Bhd, which bought back 8.94 million or 0.72% of its shares for RM69.9 million in the open market last Friday, dropped 3.98% or 31 sen to RM7.47, valuing the stock at RM61.47 billion. The counter was the seventh biggest loser as at the time of writing. The smaller players were also not spared from the selling pressure. Kossan Rubber Industries Bhd lost 4.2% or 28 sen to RM6.38, Careplus Group Bhd fell 6.58% or 20 sen to RM2.84, and Comfort Gloves Bhd shed 4.71% or 19 sen to RM3.84. The Healthcare Index was dragged down by the glove stocks, declining by 1.75% or 69.68 points to 3,921.47. Last week, Pfizer and its German partner BioNTech announced that their experimental Covid-19 vaccine was more than 90% effective with no serious safety concerns based on initial trial results. They also estimated that they can roll out up to 50 million doses this year for 25 million people and produce 1.3 billion doses in 2021.
Govt has communicated with 10 Covid-19 vaccine producers, says Khairy KUALA LUMPUR (Nov 16): The government has communicated with 10 Covid-19 vaccine producers following a notification by the World Health Organization (WHO) that there are 11 Covid-19 vaccine candidates in phase 3 clinical trial (as of Nov 13). Science, Technology and Innovation Minister Khairy Jamaluddin said communications with eight of the producers was made directly, while the other two was through the Covid-19 Vaccine Global Access Facility (COVAX). He said some of the discussions are in the final stage and an official announcement would be made when everything has been finalised. “The discussion covers aspects of cooperation in various stages of vaccine development such as R&D (research and development), exchange of scientists, fill and finish development (transfer of technology, logistics, cold chain), including the purchase of vaccines (finished products) as a guarantee of access to vaccine supply for the country," he said during the questions for oral answers session in the Dewan Rakyat today. He was responding to a question from Chan Foong Hin (Pakatan Harapan-Kota Kinabalu) who wanted to know whether the ministry had made any order to import vaccines from companies from China, such as Cansino, Sinovac and Sinopharm, or the UK, such as AstraZeneca, and whether the ministry would set the order of priority for Covid-19 vaccination as being done in Indonesia. Khairy said through participation in COVAX, Malaysia would have access to the supply of Covid-19 vaccine of 10% of the country's population and the government was working to get another 60% to meet the national immunisation target for herd immunity to up to 70 per cent of the country's population. The government, he said, was also working to get vaccine access as early as the first or second quarter of next year depending on the approval from the National Pharmaceutical Regulatory Agency (NPRA). He said the NPRA will ensure that a vaccine passes the stipulated strict conditions, covering its safety and effectiveness through data on the clinical trial that was conducted. Meanwhile, on the list of immunisation priorities, Khairy said the Special Committee on Covid-19 Vaccine Supply Access (JKJAV), set up on Oct 14 , had agreed to divide it into three groups, namely the frontliners, involving staff of the Ministry of Health (MoH) and agencies not under the MoH, such as the police, the Malaysian Armed Forces, Immigration Department and others, in the first group. The second is for high-risk groups, such as individuals with co-morbid and seniors citizens, and the third involves other adult population. Details of the groups are being made and the announcement is expected to be made during the first quarter of next year.
RENOUNCEABLE RIGHTS ISSUE OF UP TO 828,573,600 NEW ORDINARY SHARES IN GREEN OCEAN AT AN ISSUE PRICE OF RM0.10 PER RIGHTS SHARE TOGETHER WITH UP TO 621,430,200 FREE DETACHABLEWARRANTS IN GREEN OCEAN ON THE BASIS OF 4 RIGHTS SHARES TOGETHER WITH 3 FREE WARRANTS B FOR EVERY 2 EXISTING SHARES HELD BY THE ENTITLED SHAREHOLDERS OF THE COMPANY AT 5.00 P.M. ON 2 DECEMBER 2020
If you buy 1 shares at 16 sen, you will given the right to subcribe 2 shares at 10 sen each and get 1.5 warrants free. Total cost = 16 + 2(10) = 36 sen Average price after the exercise = 36/3 = 12 sen. If the price above 12 sen on the listing day then you will make money + the sales from 1.5 warrants (should be in the range of 5 to 10 sen if the conversion price is 10 sen). Is it worth to buy before the x-date?
@ trader1668 if next week price no drop to your expectation range I will advise you collect at market price as this show Gocean attract retailers interest to join right issue.
@ trader1668 @Engcccc....i hold a bit ..will collect when it further down some.... think this share has it's potential with good news coming soon! 21/11/2020 12:27 PM
The operator shd push the price to 25c before ex date. If the share price go up to 25c. The average cost or ex date price will be 15c. A 5c gap between 10c rights price and current share price is safer for rights subsciber.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
1300177
37 posts
Posted by 1300177 > 2020-11-14 14:12 | Report Abuse
Any update for the glove factory